A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

PURPOSE: Clostridium difficile infection (CDI) represents a significant economic healthcare burden, especially the cost of recurrent disease. Fidaxomicin produced significantly lower recurrence rates and higher sustained cure rates in clinical trials. We evaluated the cost-effectiveness and budget i...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Infection
Huvudupphovsmän: Watt, Maureen, McCrea, Charles, Johal, Sukhvinder, Posnett, John, Nazir, Jameel
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Berlin Heidelberg 2016
Ämnen:
Original Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042976/
https://ncbi.nlm.nih.gov/pubmed/27062378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-016-0894-y
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk